La jolla Pharmaceutical
San Diego
About La jolla Pharmaceutical
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company's second product candidate, is a natural peptide for the treatment of the hepatorenal syndrome.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $50K – $100K
- Total funding: $190.9M
- Funding stage: M&A
- Last round: Post-IPO Equity (Sep 2015)
- Ticker: nasdaq:LJPC
- Website: lajollapharmaceutical.com
- Phone: (858)207-4264
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/la-jolla-pharmaceutical-2902347 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.